Jirundon Yuvaniyama

Jirundon Yuvaniyama

Auto-generated profile, based on publicly available information

Jirundon Yuvaniyama

Department of Biochemistry and Center for Excellence in Protein Structure and Function, Faculty of Science, Mahidol University, Rama 6 Road, Phayathai, Bangkok 10400, Thailand

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 April 2003 in Nature Structural & Molecular Biology
Verified
Journal Article
Closed access
JYJirundon Yuvaniyama
Jirundon Yuvaniyama
PCPenchit Chitnumsub
Penchit Chitnumsub
SKSumalee Kamchonwongpaisan
Sumalee Kamchonwongpaisan
JVJarunee Vanichtanankul
Jarunee Vanichtanankul
WSWorachart Sirawaraporn
Worachart Sirawaraporn
YYYongyuth Yuthavong
Yongyuth Yuthavong

31 May 1996 in Science
Verified
Journal Article
Closed access
PDF file
JYJirundon Yuvaniyama
Jirundon Yuvaniyama
JDJohn M. Denu
John M. Denu
JDJack E. Dixon
Jack E. Dixon
MSMark A. Saper
Mark A. Saper
Dual specificity protein phosphatases (DSPs) regulate mitogenic signal transduction and control the cell cycle. Here, the crystal structure of a human DSP, vaccinia H1-related phosphatase (or VHR), was determined at 2.1 angstrom resolution. A shallow active site pocket in VHR allows for the hydrolysis of phosphorylated serine, threonine, or tyrosine protein residues, whereas the deeper active site of protein tyrosine phosphatases (PTPs) restricts substrate specificity to only phosphotyrosine. Positively charged crevices near the active site may explain the enzyme's preference for substrates with two phosphorylated residues. The VHR structure defines a conserved structural scaffold for both DSPs and PTPs. A "recognition region," connecting helix α1 to strand β1, may determine differences in substrate specificity between VHR, the PTPs, and other DSPs.

3 October 2012 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
YYYongyuth Yuthavong
Yongyuth Yuthavong
BTBongkoch Tarnchompoo
Bongkoch Tarnchompoo
TVTirayut Vilaivan
Tirayut Vilaivan
PCPenchit Chitnumsub
Penchit Chitnumsub
SKSumalee Kamchonwongpaisan
Sumalee Kamchonwongpaisan
DMDavid Matthews
David Matthews
Malarial dihydrofolate reductase (DHFR) is the target of antifolate antimalarial drugs such as pyrimethamine and cycloguanil, the clinical efficacy of which have been compromised by resistance arising through mutations at various sites on the enzyme. Here, we describe the use of cocrystal structures with inhibitors and substrates, along with efficacy and pharmacokinetic profiling for the design, characterization, and preclinical development of a selective, highly efficacious, and orally available antimalarial drug candidate that potently inhibits both wild-type and clinically relevant mutated forms of Plasmodium falciparum (Pf) DHFR. Important structural characteristics of P218 include pyrimidine side-chain flexibility and a carboxylate group that makes charge-mediated hydrogen bonds with conserved Arg122 (PfDHFR-TS amino acid numbering). An analogous interaction of P218 with human DHFR is disfavored because of three species-dependent amino acid substitutions in the vicinity of the conserved Arg. Thus, P218 binds to the active site of PfDHFR in a substantially different fashion from the human enzyme, which is the basis for its high selectivity. Unlike pyrimethamine, P218 binds both wild-type and mutant PfDHFR in a slow-on/slow-off tight-binding mode, which prolongs the target residence time. P218, when bound to PfDHFR-TS, resides almost entirely within the envelope mapped out by the dihydrofolate substrate, which may make it less susceptible to resistance mutations. The high in vivo efficacy in a SCID mouse model of P. falciparum malaria, good oral bioavailability, favorable enzyme selectivity, and good safety characteristics of P218 make it a potential candidate for further development.

1 November 2004 in Parasitology
Verified
Journal Article
Closed access
PDF file
YYY. Yuthavong
Y. Yuthavong
JYJ. Yuvaniyama
J. Yuvaniyama
PCP. Chitnumsub
P. Chitnumsub
JVJ. Vanichtanankul
J. Vanichtanankul
SCS. Chusacultanachai
S. Chusacultanachai
SKS. Kamchonwongpaisan
S. Kamchonwongpaisan
Dihydrofolate reductase-thymidylate synthase (DHFR-TS) from Plasmodium falciparum, a validated target for antifolate antimalarials, is a dimeric enzyme with interdomain interactions significantly mediated by the junction region as well as the Plasmodium-specific additional sequences (inserts) in the DHFR domain. The X-ray structures of both the wild-type and mutant enzymes associated with drug resistance, in complex with either a drug which lost, or which still retains, effectiveness for the mutants, reveal features which explain the basis of drug resistance resulting from mutations around the active site. Binding of rigid inhibitors like pyrimethamine and cycloguanil to the enzyme active site is affected by steric conflict with the side-chains of mutated residues 108 and 16, as well as by changes in the main chain configuration. The role of important residues on binding of inhibitors and substrates was further elucidated by site-directed and random mutagenesis studies. Guided by the active site structure and modes of inhibitor binding, new inhibitors with high affinity against both wild-type and mutant enzymes have been designed and synthesized, some of which have very potent antimalarial activities against drug-resistant P. falciparum bearing the mutant enzymes.

1 April 2008 in Journal of Molecular Biology
Verified
Journal Article
Closed access
WCWatchalee Chuenchor
Watchalee Chuenchor
SPSalila Pengthaisong
Salila Pengthaisong
RRRobert C. Robinson
Robert C. Robinson
JYJirundon Yuvaniyama
Jirundon Yuvaniyama
WOWorrapoj Oonanant
Worrapoj Oonanant
James Ketudat CairnsJames Ketudat Cairns
James Ketudat Cairns

1 February 1995 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
JDJohn M. Denu
John M. Denu
GZGaochao Zhou
Gaochao Zhou
LWLi Wu
Li Wu
RZRong Zhao
Rong Zhao
JYJirundon Yuvaniyama
Jirundon Yuvaniyama
JDJack E. Dixon
Jack E. Dixon
An expression and purification method was developed to obtain the recombinant human dual-specific protein tyrosine phosphatase (PTPase) VHR in quantities suitable for both kinetic studies and crystallization. Physical characterization of the homogeneous recombinant protein verified the mass to be 20,500 ± 100 by matrix-assisted laser desorption mass spectrometry, confirmed the anticipated NH2-terminal amino acid sequence and demonstrated that the protein exists as a monomer. Conditions were developed to obtain crystals which were suitable for x-ray structure determination. Using synthetic diphosphorylated peptides corresponding to MAPGraphic (mitogen-activated protein) kinase (DHTGFLpTEpYVATR), an assay was devised which permitted the determination of the rate constants for dephosphorylation of the diphosphorylated peptide on threonine and tyrosine residues. The diphosphorylated peptides are preferred over the singly phosphorylated on tyrosine by 3-8-fold. The apparent second-order rate constant kGraphic/KGraphic for dephosphorlyation of phosphotyrosine on DHTGFLpTEpYVATR was 32,000 MGraphic sGraphic while dephosphorylation of phosphothreonine was 14 MGraphic sGraphic (pH 6). The reaction of DHTGFLpTEpYVATR with VHR is ordered, with rapid dephosphorylation on tyrosine occurring first followed by slow dephosphorylation on threonine. Similar results were obtained with F(NLe)(NLe)pTPpYVVTR, a peptide corresponding to a MAP kinase-like protein (JNK1Graphic) which is involved in the stress response signaling pathway.